BSEGeneral2d ago · 13 Oct 2026, 12:18 pm
The Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, has approved the following: 1. Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company 2. Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director of the Company
Senores Pharmaceuticals Ltd · 544319
✦ AI SummaryMgmt Change
The Board of Directors of Senores Pharmaceuticals Ltd has approved the re-appointment of Mr. Swapnil Jatinbhai Shah as the Managing Director and Mr. Chetan Bipinchandra Shah as the Whole Time Director of the Company, both for a period of three consecutive years, subject to shareholder approval.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting
Attachments (1)
📄pdf
Download →
029cedcc-4f82-43d9-9325-4fed3563f1ca.pdf
View document text
Date: October 13, 2026
To, To,
Sr. General Manager Sr. General Manager
Listing Department Listing Department
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G
Dalal Street Bandra Kurla Complex
Mumbai – 400 001 Bandra (E), Mumbai – 400 051
BSE Scrip Code: 544319 NSE Symbol: SENORES
Dear Sir/Madam,
Sub.: Outcome of Board Meeting of the Company held on Tuesday, October 13, 2026
With reference to the captioned subject, we wish to inform you that the Board of Directors of the
Company at their Meeting held today i.e., Tuesday, October 13, 2026, has inter-alia, approved the
following:
1. Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the
Company
Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors
of the Company have approved the re-appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the
Managing Director of the Company, liable to retire by rotation for a period of three (3) consecutive years
w.e.f. October 15, 2026 subject to the approval of shareholders to be obtained through postal ballot
process.
The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No.
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- A.
2. Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director
of the Company
Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors
of the Company have approved the re-appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971)
as the Whole Time Director of the Company, liable to retire by rotation for a period of three (3)
consecutive years w.e.f. November 10, 2026 subject to the approval of shareholders to be obtained
through postal ballot process.
The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No.
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- B.
Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India
P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263
Kindly note that the meeting of Board of Directors of the Company commenced at 11:30 AM (IST) and
concluded at 11:55 PM (IST).:
This intimation and aforesaid information are also being uploaded on the Company’s website at
www.senorespharma.com.
You are requested to take the same on record.
Thanking you.
For Senores Pharmaceuticals Limited
Shilpa Sharma
Company Secretary & Compliance Officer
ICSI Membership No.: A34516
Enclosures: As above
Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India
P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263
Annexure-A
Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the
Company
Sr. Particulars Details
1. Reason for change viz. appointment, Re-Appointment of Mr. Swapnil Jatinbhai Shah
re-appointment, resignation, removal, (DIN: 05259821) as the Managing Director of the
death or otherwise Company.
2. Date of appointment/re- For a further period of three (3) consecutive years
appointment/cessation (as applicable) w.e.f. October 15, 2026 subject to the approval of
and term of appointment shareholders to be obtained through postal ballot
process.
3. Brief Profile (in case of re- Mr. Swapnil Jatinbhai Shah is the Promoter and
appointment) Managing Director of the Company. He has over 15
years of experience in the pharmaceutical sector.
He was previously involved in business operations
in a Delaware based pharmaceutical company. He is
currently leading the Company’s overall
functioning and is a part of the core management
team. He is also responsible for product portfolio
management, corporate strategy, business
development and overall strategic management of
our Company. He holds a master’s degree in
business administration from Hofstra University,
New York and a bachelor’s degree in chemical
engineering from Nirma University. He was
previously associated as a strategist at Planet
Payment Inc. (now acquired by Fintrx, Inc., a fintech
company listed on the NASDAQ). He is a convenor
of the pharma panel in the Confederation of Indian
Industry (CII), Gujarat State Council.
4. Disclosure of relationships between Mr. Swapnil Jatinbhai Shah is not related inter-se to
directors (in case of re-appointment of any other Directors of Company.
a director)
5. Information as required under BSE Mr. Swapnil Jatinbhai Shah is not debarred from
circular no. LIST/COMP/14/2018- 19 holding the office of Director by virtue of any SEBI
and NSE circular no. order or any other such authority.
NSE/CML/2018/24, dated June 20,
2018
Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India
P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263
Annexure-B
Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director
of the Company
Sr. Particulars Details
1. Reason for change viz. appointment, Re-Appointment of Mr. Chetan Bipinchandra Shah
re-appointment, resignation, removal, (DIN: 10381971) as the Whole-time Director of the
death or otherwise Company.
2. Date of appointment/re- For a further period of three (3) consecutive years
appointment/cessation (as applicable) w.e.f. November 10, 2026 subject to the approval of
and term of re-appointment shareholders to be obtained through postal ballot
process.
3. Brief Profile (in case of re- Mr. Chetan Bipinchandra Shah is the Whole-Time
appointment) Director and Chief Operating Officer of the
Company. He has over 30 years of experience of
which 25 years of experience is in the
pharmaceutical industry and was previously
associated with pharmaceutical companies such as
Torrent Pharmaceuticals Limited and Cadila
Pharmaceuticals Limited. He was also associated
with Reliance Retail Limited, Reliance Fresh
Limited and Reliance Corporate IT Park Limited. He
is a part of the core management team of the
Company and is responsible for strategy planning,
capital expenditure planning, capacity expansion,
policy enforcement, mergers and acquisitions,
supply chain for both domestic and international
chain, manufacturing processes and automation,
risk management and overall management
information system.
4. Disclosure of relationships between Mr. Chetan Bipinchandra Shah is not related inter-
directors (in case of re-appointment of se to any other Directors of Company.
a director)
5. Information as required under BSE Mr. Chetan Bipinchandra Shah is not debarred from
circular no. LIST/COMP/14/2018- 19 holding the office of Director by virtue of any SEBI
and NSE circular no. order or any other such authority.
NSE/CML/2018/24, dated June 20,
2018
Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India
P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263